Amy L Heaps
Overview
Explore the profile of Amy L Heaps including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
13
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Paul M, Choudhary M, Heaps A, Deo R, Moisi D, Gordon K, et al.
Pathog Immun
. 2024 Sep;
9(2):79-93.
PMID: 39247686
Background: Anti-SARS-CoV-2 monoclonal antibodies (mAbs) have played a key role as an anti-viral against SARS-CoV-2, but there is a potential for resistance to develop. The interplay between host antibody responses...
2.
Koss C, Gandhi M, Halvas E, Okochi H, Chu C, Glidden D, et al.
Open Forum Infect Dis
. 2024 Sep;
11(9):ofae468.
PMID: 39229286
Background: Long-acting cabotegravir (CAB-LA) is highly effective for HIV prevention, but delayed HIV diagnoses and integrase strand transfer inhibitor (INSTI) resistance were observed in trials. We report the first case...
3.
Parikh U, Heaps A, Moisi D, Gordon K, Mellors J, Choudhary M, et al.
Pathog Immun
. 2024 Aug;
9(2):58-78.
PMID: 39165724
Background: Assessing the breadth and duration of antigen-specific binding antibodies provides valuable information for evaluating interventions to treat or prevent SARS-CoV-2 infection. Multiplex immunoassays are a convenient method for rapid...
4.
Parikh U, Penrose K, Heaps A, Sethi R, Goetz B, Szydlo D, et al.
J Acquir Immune Defic Syndr
. 2023 Sep;
95(1):35-41.
PMID: 37732881
Background: Clinical trials of dapivirine (DPV) vaginal ring have shown it is safe, effective, and desired by women as an HIV prevention option. The risk of drug resistance is a...
5.
Jacobs J, Haidar G, Naqvi A, McCormick K, Sobolewski M, Treat B, et al.
Open Forum Infect Dis
. 2023 Jun;
10(5):ofad278.
PMID: 37265667
Prolonged coronavirus disease 2019 may generate new viral variants. We report an immunocompromised patient treated with monoclonal antibodies who experienced rebound of viral RNA and emergence of an antibody-resistant (>1000-fold)...
6.
Heaps A, Sobolewski M, Jacobs J, Gordon K, Haidar G, Mellors J, et al.
J Virol Methods
. 2023 Mar;
316:114726.
PMID: 36996908
Accurate and rapid evaluation of SARS-CoV-2 half-maximal neutralizing antibody (nAb) titer (NT50) is an important research tool for measuring nAb responses after prophylaxis or therapeutics for COVID-19 prevention and management....
7.
Parikh U, Penrose K, Heaps A, Halvas E, Goetz B, Gordon K, et al.
J Int AIDS Soc
. 2021 Nov;
24(11):e25833.
PMID: 34762770
Introduction: A potential concern with the use of dapivirine (DPV) for HIV prevention is the selection of a drug-resistant virus that could spread and reduce the effectiveness of non-nucleoside reverse...
8.
Riddler S, Balkus J, Parikh U, Mellors J, Akello C, Dadabhai S, et al.
Clin Infect Dis
. 2018 Oct;
69(3):523-529.
PMID: 30346511
Background: A vaginal ring containing dapivirine, a non-nucleoside human immunodeficiency virus (HIV)-1 reverse transcriptase inhibitor (NNRTI), was safe and effective in preventing HIV-1 infection in African women. We examined the...